SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the appointment of Mark Rothera as Viracta’s new President and Chief Executive Officer, the independent members of Viracta’s Board of Directors approved the grant of a non-qualified stock option to Mr. Rothera to purchase 1,375,000 shares of common stock. The option vests over four years, with 25% vesting on the one-year anniversary of Mr. Rothera’s employment commencement date and the remaining 75% vesting in equal monthly increments over the succeeding 36 months, subject to Mr. Rothera’s continuous service to Viracta through each vesting date. The option has an exercise price of $5.21 per share, which is equal to the closing price of Viracta’s common stock on September 19, 2022.


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.